Sean Saint, Co-Founder and CEO of Companion Medical Named One of the Top 50 Healthcare Technology CEOs of 2020

Sean Saint, co-founder and CEO of Companion Medical, the producers of InPen, the only FDA-cleared reusable smart insulin pen system, has been named as one of the Top 50 Healthcare Technology CEOs of 2020 by The Healthcare Technology Report.

As a leader in the development of easy-to-use, affordable insulin technology, Companion Medical was founded by people with diabetes which propels their drive for continuous innovation and product development. Companion Medical’s mission is to create groundbreaking solutions that drastically improve the lives of people living with Type 1 and Type 2 diabetes.

“I never really intended to start Companion Medical. After I was diagnosed with Type 1 in 2011, I started doing the research and realized that there were no other companies providing advanced technology and insulin intelligence to the millions of people with diabetes who decide not to be tethered to an insulin pump,” explained Sean Saint, CEO and co-founder of Companion Medical. “While most other insulin-delivery companies are focused on the small minority of people who want – or can afford – to use a pump, we decided to focus on helping the vast majority of people by providing them the same insulin insights plus the freedom of an affordable, smart insulin pen. We had to do this.”

Companion Medical’s InPen is the only FDA-cleared, smart insulin pen system that combines a reusable, Bluetooth insulin pen and an intuitive mobile app that helps users take the right insulin dose, at the right time. With a custom dose calculator, dosing reminders and the ability to see active insulin, InPen takes the guesswork out of managing diabetes.

“Now more than ever, with our global community impacted by this severe pandemic, the importance of the healthcare technology field is at the forefront. An extensive process was run to evaluate the hundreds of CEOs who were nominated this year. These CEOs lead exemplary organizations in the fields of medical devices, biotech, healthcare analytics, healthcare software and other related areas,” said Jerald Hapitan, editor of The Healthcare Technology Report. “We gathered data on each nominee’s professional background and assessed them across several key areas including breadth of leadership experience in the healthcare technology industry, level of expertise and domain knowledge in their particular field, depth of their executive team’s experience, and consistency of organizational performance. The Healthcare Technology Report is pleased to announce The Top 50 Healthcare Technology CEOs of 2020.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version